Public Market Listing
4519 TSE
TSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (14 total) 14 Total Assets
10 Approved
2 Phase 3 / Filed
2 Phase 1–2 / Early
24 Diseases
Disease: All diseases (14) Non-Small Cell Lung Cancer (4) Type 2 Diabetes (3) Obesity (2) Rheumatoid Arthritis (2) Hepatocellular Carcinoma (1) Colorectal Cancer (1) Bladder Cancer (1) Small Cell Lung Cancer (1) Melanoma (1) Ovarian Cancer (1) Age-Related Macular Degeneration (1) Diabetic Macular Edema (1) Atopic Dermatitis (1) Prurigo Nodularis (1) Hypertension (1) Atherosclerotic Cardiovascular Disease (1) Osteoarthritis (1) Diffuse Large B-Cell Lymphoma (1) Follicular Lymphoma (1) Chronic Lymphocytic Leukemia (1) Focal Segmental Glomerulosclerosis (1) IgA Nephropathy (1) COVID-19 (1) Bladder / Urothelial Cancer (1)
Stage: All stages (14) Approved / Phase 4 (10) Phase 3 / Filed (2) Phase 2 Phase 1 / Preclinical
Quick filter: All (14) Non-Small Cell Lung Cancer (4) Type 2 Diabetes (3) Obesity (2) Rheumatoid Arthritis (2) Hepatocellular Carcinoma (1)
Showing 14 of 14 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved ALK Small molecule
Non-Small Cell Lung Cancer
Approved PD-L1 Monoclonal antibody
Non-Small Cell Lung Cancer Hepatocellular Carcinoma Colorectal Cancer Bladder Cancer Small Cell Lung Cancer Melanoma
Approved MEK1/2 and RAF (CRAF, BRAF) · FAK Small molecule
Approved ROS1/NTRK Small molecule
Non-Small Cell Lung Cancer
Approved Angiopoietin-2 / VEGF-A Multispecific antibody
Age-Related Macular Degeneration Diabetic Macular Edema
Wet Age-Related Macular Degeneration Approved IL-31 receptor A Monoclonal antibody
Atopic Dermatitis Prurigo Nodularis
Approved GLP-1 receptor Small molecule
Obesity Type 2 Diabetes Hypertension Atherosclerotic Cardiovascular Disease Osteoarthritis
Approved CD20 · CD20-directed Cytolytic Antibody Monoclonal antibody
Rheumatoid Arthritis Diffuse Large B-Cell Lymphoma Follicular Lymphoma Chronic Lymphocytic Leukemia
Approved Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) Small molecule
Focal Segmental Glomerulosclerosis IgA Nephropathy
Approved IL-6 receptor Monoclonal antibody
Rheumatoid Arthritis COVID-19
Phase 3 GLP-1 receptor · GLP-1/GIP receptor (dual) Peptide
Phase 3 Innate and adaptive immune activation (inactivated Streptococcus pyogenes) Bacterial immunotherapy
Bladder / Urothelial Cancer
Non-Muscle Invasive Bladder Cancer Phase 2 SGLT2 Small molecule
Phase 1 ALK Small molecule
Non-Small Cell Lung Cancer
Discontinued programmes (1) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (65 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (6) November 2026 (2) Est. primary completion 2026-11-30 ·
NCT04302025 ·
CT.gov ↗ What to watch
December 2026 (4) TARA-002 Phase 2 Lymphatic Malformation Est. primary completion 2026-12 ·
NCT05871970 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12-01 ·
NCT03758989 ·
CT.gov ↗ What to watch
Est. primary completion 2026-12-28 ·
NCT04077723 ·
CT.gov ↗ What to watch
2027 (26) January 2027 (1) February 2027 (2) Est. primary completion 2027-02-26 ·
NCT05535244 ·
CT.gov ↗ What to watch
March 2027 (2) sparsentan · Filspari Phase 2 Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome Est. primary completion 2027-03-12 ·
NCT05003986 ·
CT.gov ↗ What to watch
Atezolizumab Phase 3 Breast Cancer Est. primary completion 2027-03-31 ·
NCT04873362 ·
CT.gov ↗ What to watch
May 2027 (1) orforglipron · Foundayo Phase 3 Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases … Est. primary completion 2027-05 ·
NCT07613307 ·
CT.gov ↗ What to watch
June 2027 (4) Entrectinib Phase 1/2 Solid Tumors, CNS Tumors Est. primary completion 2027-06-30 ·
NCT02650401 ·
CT.gov ↗ What to watch
Atezolizumab Phase 2 Neoplasm Metastasis Est. primary completion 2027-06-30 ·
NCT00781612 ·
CT.gov ↗ What to watch
Est. primary completion 2027-06-30 ·
NCT03178552 ·
CT.gov ↗ What to watch
Atezolizumab Phase 3 Neoplasms Est. primary completion 2027-06-30 ·
NCT05112965 ·
CT.gov ↗ What to watch
July 2027 (3) Est. primary completion 2027-07-30 ·
NCT04524871 ·
CT.gov ↗ What to watch
Atezolizumab Phase 2 Hepatocellular Carcinoma Est. primary completion 2027-07-30 ·
NCT06096779 ·
CT.gov ↗ What to watch
August 2027 (5) Est. primary completion 2027-08-31 ·
NCT06084936 ·
CT.gov ↗ What to watch
September 2027 (3) Est. primary completion 2027-09 ·
NCT06948422 ·
CT.gov ↗ What to watch
Est. primary completion 2027-09 ·
NCT06952530 ·
CT.gov ↗ What to watch
October 2027 (3) Est. primary completion 2027-10-01 ·
NCT05207670 ·
CT.gov ↗ What to watch
November 2027 (1) enicepatide Phase 2 Obesity or Overweight Est. primary completion 2027-11-12 ·
NCT07589686 ·
CT.gov ↗ What to watch
December 2027 (1) 2028 (16) February 2028 (2) enicepatide Phase 3 Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM) Est. primary completion 2028-02-24 ·
NCT07670416 ·
CT.gov ↗ What to watch
Atezolizumab Phase 2 Ovarian Cancer Est. primary completion 2028-02-28 ·
NCT04931342 ·
CT.gov ↗ What to watch
March 2028 (3) April 2028 (2) Est. primary completion 2028-04 ·
NCT07153471 ·
CT.gov ↗ What to watch
TARA-002 Phase 3 Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma … Est. primary completion 2028-04 ·
NCT07480356 ·
CT.gov ↗ What to watch
May 2028 (1) June 2028 (1) July 2028 (4) Est. primary completion 2028-07-05 ·
NCT03768063 ·
CT.gov ↗ What to watch
enicepatide Phase 3 Obesity or Overweight Est. primary completion 2028-07-24 ·
NCT07351045 ·
CT.gov ↗ What to watch
Est. primary completion 2028-07-31 ·
NCT05583617 ·
CT.gov ↗ What to watch
August 2028 (1) enicepatide Phase 3 Obesity or Overweight, Type 2 Diabetes Mellitus Est. primary completion 2028-08-07 ·
NCT07351058 ·
CT.gov ↗ What to watch
October 2028 (1) Est. primary completion 2028-10-15 ·
NCT06072781 ·
CT.gov ↗ What to watch
December 2028 (1) 2029 (7) February 2029 (1) Atezolizumab Phase 3 Hepatocellular Carcinoma Est. primary completion 2029-02-01 ·
NCT04712643 ·
CT.gov ↗ What to watch
March 2029 (1) Est. primary completion 2029-03-30 ·
NCT03075696 ·
CT.gov ↗ What to watch
April 2029 (2) enicepatide Phase 3 Type 2 Diabetes Mellitus Est. primary completion 2029-04-02 ·
NCT07889648 ·
CT.gov ↗ What to watch
Est. primary completion 2029-04-13 ·
NCT07825064 ·
CT.gov ↗ What to watch
May 2029 (1) Atezolizumab Phase 1/2 Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Est. primary completion 2029-05-30 ·
NCT04802759 ·
CT.gov ↗ What to watch
August 2029 (1) orforglipron · Foundayo Phase 3 Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal Est. primary completion 2029-08 ·
NCT07794579 ·
CT.gov ↗ What to watch
November 2029 (1) Est. primary completion 2029-11-30 ·
NCT05533775 ·
CT.gov ↗ What to watch
2030 (3) March 2030 (1) September 2030 (2) Est. primary completion 2030-09-06 ·
NCT04246086 ·
CT.gov ↗ What to watch
Est. primary completion 2030-09-30 ·
NCT03424005 ·
CT.gov ↗ What to watch
2031 (4) January 2031 (1) Atezolizumab Phase 2 Adenocarcinoma, Pancreatic Ductal Est. primary completion 2031-01-01 ·
NCT05968326 ·
CT.gov ↗ What to watch
March 2031 (1) enicepatide Phase 3 Overweight, Obesity, Cardiovascular Disease Est. primary completion 2031-03-20 ·
NCT07918846 ·
CT.gov ↗ What to watch
August 2031 (1) orforglipron · Foundayo Phase 3 Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease Est. primary completion 2031-08 ·
NCT07241390 ·
CT.gov ↗ What to watch
October 2031 (1) TARA-002 Phase 2 Non-muscle Invasive Bladder Cancer Est. primary completion 2031-10 ·
NCT05951179 ·
CT.gov ↗ What to watch
2032 (2) February 2032 (1) Alectinib · Alecensa Phase 1/2 ALK Fusion-positive Solid or CNS Tumors Est. primary completion 2032-02-28 ·
NCT04774718 ·
CT.gov ↗ What to watch
September 2032 (1) Est. primary completion 2032-09-25 ·
NCT04589845 ·
CT.gov ↗ What to watch
2033 (1) March 2033 (1) Est. primary completion 2033-03-01 ·
NCT05862285 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (13) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
9 October 2026 Approval Atezolizumab FDA approves Tecentriq for adjuvant stage III dMMR colon cancer 22 September 2026 Topline result enicepatide CT-388-104 Phase 2 (NCT06628362) in type 2 diabetes met both primary endpoints (HbA1c and body weight) 14 April 2026 Approval sparsentan FDA approves FILSPARI for FSGS 1 April 2026 Approval orforglipron FDA approves Foundayo (orforglipron) for weight management 1 April 2026 Approval orforglipron FDA Boxed Warning on Foundayo (NDA220934) 18 December 2025 Topline result orforglipron ATTAIN-MAINTAIN: orforglipron met primary endpoint 7 October 2025 FDA action date Atezolizumab PDUFA date set for October 7, 2025 2 October 2025 Approval Atezolizumab FDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC 21 June 2025 Topline result orforglipron ACHIEVE-1 Phase 3 detailed results published in NEJM 10 June 2025 Filing accepted Atezolizumab FDA accepts sNDA for Zepzelca plus atezolizumab 10 June 2025 Priority review Atezolizumab FDA grants Priority Review The 12 most recent of 13 past events are shown.
Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $8.4B $1.3B — — report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $7.7B — — — report ↗
Latest financial report · 2025-FY
Chugai reported revenue of $8,405.9M, up 8.6% YoY, with R&D spend of $1,253.63M. Cash position was not disclosed, though the company reported core net income of ¥451.0 billion, up 13.6% YoY, alongside core operating profit of ¥623.2 billion.
For 2026, Chugai guided to record core revenue of ¥1,345.0 billion (+6.9% YoY), core operating profit of ¥670.0 billion (+7.5%), and core net income of ¥485.0 billion (+7.5%). Key pipeline events included NXT007 achieving proof of concept in hemophilia A, Eli Lilly submitting an FDA new drug application for orforglipron in obesity, European approval of NEMLUVIO, and FDA accelerated approval of AVMAPKI. Sparsentan showed positive Phase III topline results in IgA nephropathy with a planned 2026 filing in Japan, and new research partnerships with Gero and Rani Therapeutics were announced.